期刊
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
卷 24, 期 -, 页码 335-339出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jgar.2021.01.014
关键词
Ceftobiprole; CLEAR registry; Efficacy; Adverse effects; Pneumonia; Endocarditis
资金
- Health Sciences Centre (Winnipeg, Manitoba, Canada)
- University of Manitoba (Winnipeg, Manitoba, Canada)
- AVIR Pharma (Montreal, Quebec, Canada)
- Merck Canada (Montreal, Quebec, Canada)
- Verity (Toronto, Ontario, Canada)
Ceftobiprole is used in Canada as a directed therapy for treating severe infections caused by MRSA, often in combination with daptomycin or vancomycin. Treatment duration is typically over 10 days, with high rates of microbiological and clinical success and a good safety profile.
Objectives: Ceftobiprole is an advanced-generation cephalosporin with a favourable safety profile. Published data on the clinical use of ceftobiprole are limited. We report use of ceftobiprole in Canadian patients using data captured by the CLEAR registry. Methods: The CLEAR registry uses the web-based research data management program REDCap (TM) (online survey) to facilitate clinicians entering details associated with their clinical experiences using ceftobiprole. Results: Data were available for 38 patients treated with ceftobiprole. The most common infections treated were endocarditis (42.1% of patients), bone and joint infection (23.7%) and hospital-associated bacterial pneumonia (15.8%). 92.1% of patients had bacteraemia and 21.1% were in intensive care. Ceftobiprole was used because of failure of (71.1%), resistance to(18.4%) or adverse effects from (10.5%)previously prescribed antimicrobial agents. Ceftobiprole was primarily used as directed therapy for methicillin-resistant Staphylococcus aureus (MRSA) infections (94.7% of patients). Ceftobiprole susceptibility testing was performed on isolates from 47.4% of patients. It was used concomitantly with daptomycin in 55.3% of patients and with vancomycin in 18.4% of patients. Treatment duration was primarily >10 days (65.8% of patients) with microbiological success in 97.0% and clinical success in 84.8% of patients. 2.6% of patients had gastrointestinal adverse effects. Conclusion: In Canada to date, ceftobiprole is used as directed therapy to treat a variety of severe infections caused by MRSA. It is primarily used in patients failing previous antimicrobials, is frequently added to, and thus used in combination with daptomycin or vancomycin with high microbiological and clinical cure rates and an excellent safety profile. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据